BONUS BIOGROUP (TASE: BONS) is a biotechnology company applying proprietary, innovative technology to supply tissue-engineered viable bone grafts.
The company strives to become a world leader in the field of tissue engineering and live bone transplantation.
News and Press Release
- Wednesday, 20 May 2020
Successful treatment of acute pneumonia, demonstrating that following the administration of MesenCure, the treated lung appeared as a healthy lung
Read >> - Wednesday, 13 May 2020
Preliminary pre-clinical study results with the unique drug product MesenCure, developed by Bonus Biogroup for the treatment of life-threatening respiratory distress in COVID-19 and pneumonia patients
Read >> - Sunday, 19 April 2020
Bonus BioGroup has initiated a preclinical study of a unique drug developed for the treatment of life-threatening respiratory distress in Corona (COVID-19) patients and pneumonia
Read >>
Wednesday, 22 January 2020 17:24
Confirmation of issued patent in Europe, which in concert with the issued patents in the USA and Australia, provides Bonus BioGroup the exclusive rights for the commercialization in 70% of the world population with a high income profile1, in a world market estimated at USD 8 billion
Read >>
- Sunday, 02 September 2018 17:24
Bonus BioGroup raises investment in the amount of NIS 18 million (USD 5 million), at a price of 60 Agorot per share
Read >>
Products
Bonus BioGroup has developed a novel method to grow bone grafts from cells derived from the patient's fat tissue. The graft is precisely fit to the injured bone site and rapidly integrates in the patient's body.
BonoFillTM products family
Exclusive 3D, high-density bone grafts, grown from the cells derived from the patient's fat tissue, obtained in a simple procedure. Heterogeneous population of cells are then cultured and expanded in a bioreactor system, on a supportive matrix (scaffold), and induced to generate the bone graft. The graft is precisely fit to the injured bone site and rapidly integrates in the patient's body.
Injectable bone graft
Anatomically pre-designed bone graft
Appropriate for defined defects, such as maxillofacialbone voids and cysts.
A cut to shape graft, match the dimensions of the patient's bone gap, determine using CT imaging
Clinical Trial
Orthopedic
In August, 2017 Bonus announced the first live human bone graft, grown outside the patient's body, transplanted into a patient’s arm as part of a clinical trial for reconstruction of extensive critical bone loss in bones of the extremities.
Maxillofacial Bone Regeneration
Bonus BioGroup commenced a clinical trial to evaluate the safety and efficacy of BonoFillTM in the treatment of human maxillofacial bone deficiency. BonoFillTM is regulated under the category of Advanced Therapy Medicinal Product (ATMP) that complies with the definition of Somatic Cell Therapies, and was developed according to GMP and GCP principles.
SCIENCE & TECHNOLOGY
Bone reconstruction is medically required to repair an injured bone arise in a multitude of situations of trauma and bone diseases. The ideal bone graft is biocompatible, functionally and structurally similar to the patient's bone, easily transplantable and cost-effective. Failure rates of current techniques have encouraged researchers to seek new biomaterials promoting bone regeneration.
Adipose tissue has significant advantages as a cell source for tissue engineering products. Human Adipose Tissue-Derived Cells (HATDCs) can differentiate along multiple cell lineage pathways to form various types of mature cells, and can be safely and effectively transplanted back into the patient.